QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,106 signal articles · 530 in last 24h · 103,813 total before filter · latest 29m ago
530last 24h
2505last 7d
477● bullish (7d)
254● bearish (7d)
197publishers
AllMacro229Earnings1481M&A143Regulatory15Product5Analyst29
✕ clear all filtersticker: GENBSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)
Insider Monkey42d agoneutral
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB)

Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the 12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On. On May 14, Morgan Stanley increased its price objective on Generate Biomedicines, Inc. (NASDAQ:GENB) to $22 from $20. The firm maintained an “Overweight” rating on the shares. Separately, Generate Biomedicines, Inc. (NASDAQ:GENB)’s GB-0895 (anti-TSLP) program […]